Recently approved RSV prevention therapies may be next FDA target

The FDA has opened a safety review of recently approved RSV monoclonal antibody prophylactics—Beyfortus (nirsevimab), approved in 2023, and Enflonsia (clesrovimab‑cfor), approved this summer—after questions about potential seizure risks raised publicly (including by U.S. Health Secretary Robert F. Kennedy Jr.) and internally by senior FDA adviser Tracy Beth Hoeg, prompting the agency’s CDER to request additional safety data from Merck, Sanofi and AstraZeneca. Several studies and manufacturers dispute a seizure link—Sanofi cites more than 50 studies covering over 400,000 infants—and CDC data show Beyfortus use correlated with a 43% reduction in infant RSV hospitalizations in 2024‑25 versus 2018‑20, but regulators and public‑health officials say post‑marketing surveillance and further data review (including by CDC/ACIP) are warranted given the widespread use of these agents to protect infants in their first 6–12 months and RSV’s role in 2–3% of infant hospitalizations each season.

Analysis

The FDA has opened a safety review of recently approved RSV monoclonal antibody prophylactics — Beyfortus (nirsevimab), approved in 2023, and Enflonsia (clesrovimab-cfor), approved this summer — after internal concerns raised by senior FDA adviser Tracy Beth Hoeg in June and public questions from U.S. Health Secretary Robert F. Kennedy Jr., prompting CDER to request further safety data from Merck, Sanofi and AstraZeneca following a call last week. The alleged seizure link originated in a summer blog post by an Australian journalist, but several studies cited in reporting have found no signals of increased seizure risk to date. Sanofi cites safety evidence from more than 50 studies covering over 400,000 infants, and CDC data show Beyfortus use coincided with a 43% reduction in infant RSV hospitalizations in the 2024–25 season versus 2018–2020, while RSV remains responsible for roughly 2%–3% of infant hospitalizations each season. The inquiry increases regulatory and reputational risk for the manufacturers in the near term; the NFID vice president’s comment that post‑marketing data should be reviewed by CDC/ACIP highlights that subsequent CDC and ACIP assessments and any post‑marketing reports will be the key drivers of commercial uptake and market reaction, consistent with a mixed, cautious market tone and a modest market impact score of 0.32.

Key Decisions for Investors

• Monitor CDER's review timeline and the specific safety data requested from Merck, Sanofi and AstraZeneca and delay increasing exposure to these firms' RSV franchises until the agency and CDC/ACIP conclusions are public
• Factor in Sanofi's >50‑study, >400,000‑infant safety claim and the CDC's reported 43% reduction in RSV hospitalizations when assessing long‑term demand risk — avoid knee‑jerk divestitures absent concrete post‑marketing adverse signals
• Use position sizing or short‑term hedges for healthcare/biotech exposure given the elevated regulatory uncertainty and a market impact score of 0.32 that suggests modest near‑term volatility
• Treat CDC/ACIP statements, any post‑marketing seizure reports, or labeling/safety communications as trigger events to reassess and potentially reprice positions in the affected manufacturers